Astena Holdings (8095) · InitiativeAdvanced
Joint development of a new drug formulation with Kinopharma
First written in FY2022-Q1. 1 of 2 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2022-Q3.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Joint development and commercialization of a new drug formulation with キノファーマA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022-Q3AdvancedAnnual report
「Sales remained firm, supported by achievements including obtaining approval for Japan's first new generic drug product for future growth, signing a joint development and commercialization agreement with キノファーマ, and transferring the function of a beauty medical brand holder.」
The joint development of new drug formulations with キノファーマ progressed to the signing of a joint development and commercialization agreement. Obtaining approval for Japan's first new generic drug product was also cited as an achievement. - FY2022-Q1First statedAnnual report
「The joint development of new drug formulations with キノファーマ, an investee company, also progressed smoothly.」
The joint development of new drug formulations with investee company キノファーマ was mentioned for the first time and was described as progressing smoothly.